How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG? [PDF]
Appl Health Econ Health Policy, 2022 Dintsios CM, Chernyak N.
europepmc +1 more source
AMNOG verändert die Verschreibungspraxis [PDF]
MMW - Fortschritte der Medizin, 2011 openaire +2 more sources
Joint Clinical Assessment in the EU HTA Regulation-Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? [PDF]
J Mark Access Health PolicyKloc K +9 more
europepmc +1 more source
Fampridin laut AMNOG erstattungsfähig [PDF]
DNP - Der Neurologe und Psychiater, 2013 openaire +1 more source
Conditional Resolutions in the Amnog Early Benefit Assessment [PDF]
Value in Health, 2014 Assmann, G. +3 more
openaire +2 more sources
Do conditional marketing authorisations actually accelerate patient access? Time-to-access of conditional vs. standard marketing authorisations in Italy, Spain, and Germany. [PDF]
J Pharm Policy PractArdito V +6 more
europepmc +1 more source
The Impact of Amnog on Drug Reimbursement in Germany [PDF]
Value in Health, 2013 Heeg, B. +3 more
openaire +1 more source
EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making. [PDF]
J Mark Access Health PolicyJohns A, Andrade A, Johal S, Ryan J.
europepmc +1 more source
Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information. [PDF]
J Eur CME, 2021 McGauran N, Wieseler B.
europepmc +1 more source